

Mirtazapine Solid Formulation

Version 3.11 Revision Date: 2020/03/23 SDS Number: 50159-00015 Date of last issue: 2019/09/13
Date of first issue: 2015/01/23

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mirtazapine Solid Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : JL Raya Pandaan KM. 48
Pandaan, Jawa Timur - Indonesia

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION**GHS Classification**

Reproductive toxicity : Category 2

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Nervous system)

Long-term (chronic) aquatic hazard : Category 3

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H373 May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust.

P273 Avoid release to the environment.

Mirtazapine Solid Formulation

Version 3.11 Revision Date: 2020/03/23 SDS Number: 50159-00015 Date of last issue: 2019/09/13
 Date of first issue: 2015/01/23

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	>= 10 -< 25
Starch	9005-25-8	>= 10 -< 30

4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
 Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
 Remove contaminated clothing and shoes.
 Get medical attention.
 Wash clothing before reuse.
 Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
 Get medical attention.
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of damaging fertility. Suspected of damaging the unborn child.
 May cause damage to organs through prolonged or repeated exposure if swallowed.

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2019/09/13
3.11	2020/03/23	50159-00015	Date of first issue: 2015/01/23

Protection of first-aiders	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Silicon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	:	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

SAFETY DATA SHEET



Mirtazapine Solid Formulation



Version 3.11 Revision Date: 2020/03/23 SDS Number: 50159-00015 Date of last issue: 2019/09/13
Date of first issue: 2015/01/23

mine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	TWA	25 µg/m ³	Internal
		Wipe limit	250 µg/100 cm ²	Internal
Starch	9005-25-8	NAB	10 mg/m ³	ID OEL
	Further information: Adopted in Year 1996, Not classified as carcinogenic to humans. Not enough data to classify these materials as carcinogenic to humans or animals			
		TWA	10 mg/m ³	ACGIH

- Engineering measures** : Ensure adequate ventilation, especially in confined areas.
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are de-

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2019/09/13
3.11	2020/03/23	50159-00015	Date of first issue: 2015/01/23

signed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
- Eye protection : Wear the following personal protective equipment:
Safety goggles
- Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Colour : No data available
- Odour : No data available
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : Not applicable
- Evaporation rate : No data available
- Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

SAFETY DATA SHEET



Mirtazapine Solid Formulation



Version 3.11 Revision Date: 2020/03/23 SDS Number: 50159-00015 Date of last issue: 2019/09/13
Date of first issue: 2015/01/23

		dling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2019/09/13
3.11	2020/03/23	50159-00015	Date of first issue: 2015/01/23

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Starch:**

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Starch:**

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2019/09/13
3.11	2020/03/23	50159-00015	Date of first issue: 2015/01/23

Germ cell mutagenicity

Not classified based on available information.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: unscheduled DNA synthesis assay
Test system: mammalian cells
Result: negative

Test Type: sister chromatid exchange assay
Test system: mammalian cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Rat
Cell type: Bone marrow
Application Route: Oral
Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Mouse
Application Route : Oral
Exposure time : 18 month(s)
LOAEL : 200 mg/kg body weight
Result : equivocal
Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years
LOAEL : 20 mg/kg body weight
Result : equivocal
Target Organs : Liver, Thyroid

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Mirtazapine Solid Formulation

Version 3.11 Revision Date: 2020/03/23 SDS Number: 50159-00015 Date of last issue: 2019/09/13
 Date of first issue: 2015/01/23

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

- Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Oral
 Fertility: LOAEL: 15 mg/kg body weight
 Symptoms: Effect on estrous cycle, Increase of early resorptions
 Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.
- Effects on foetal development : Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: LOAEL: 100 mg/kg body weight
 Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects
- Test Type: Development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: NOAEL: 40 mg/kg body weight
 Result: No adverse effects, No teratogenic effects
- Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

Components:**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

- Exposure routes : Ingestion
 Target Organs : Nervous system
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

- Species : Rat
 LOAEL : 120 mg/kg
 Application Route : Oral
 Exposure time : 13 Weeks

Mirtazapine Solid Formulation

Version 3.11 Revision Date: 2020/03/23 SDS Number: 50159-00015 Date of last issue: 2019/09/13
 Date of first issue: 2015/01/23

Target Organs : Nervous system

Species : Dog
 LOAEL : 15 mg/kg
 Application Route : Oral
 Exposure time : 52 Weeks
 Target Organs : Nervous system
 Symptoms : Tremors

Species : Dog
 LOAEL : 20 mg/kg
 Application Route : Oral
 Exposure time : 13 Weeks
 Target Organs : Nervous system, Testis
 Symptoms : Tremors

Starch:

Species : Rat
 NOAEL : >= 2,000 mg/kg
 Application Route : Skin contact
 Exposure time : 28 Days
 Method : OECD Test Guideline 410

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Ingestion : Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l
 Exposure time: 96 h
 Method: FDA 4.11

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 19.5 mg/l
 aquatic invertebrates : Exposure time: 48 h

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7
 plants : mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2

Mirtazapine Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2019/09/13
3.11	2020/03/23	50159-00015	Date of first issue: 2015/01/23

mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 3.6 mg/l
Exposure time: 31 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.32 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

No data available

Bioaccumulative potential**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)
Bioconcentration factor (BCF): 334
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 2.78

Mobility in soil**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Distribution among environmental compartments : log Koc: 4.48

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Mirtazapine Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2019/09/13
3.11 2020/03/23 50159-00015 Date of first issue: 2015/01/23

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health

Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

Regulation of the Minister of Trade No. 44 of 2009 on Procurement, Distribution and Supervision of Hazardous Materials

Type of Hazardous Materials Restricted to Import, Distribution and Supervision : Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SAFETY DATA SHEET



Mirtazapine Solid Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 2019/09/13
3.11	2020/03/23	50159-00015	Date of first issue: 2015/01/23

16. OTHER INFORMATION

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ID OEL : Indonesia. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average
ID OEL / NAB : Long term exposure limit

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

SAFETY DATA SHEET



Mirtazapine Solid Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 2019/09/13
3.11	2020/03/23	50159-00015	Date of first issue: 2015/01/23

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN